Following encouraging preclinical data, several clinical studies which invest AAV‐GDNF and AAV‐NRTN gene therapy in PD patients were conducted.[134, 135, 136] However, the impact of the clinical outcomes remains limited owing to insufficient therapeutic efficacy. Here, GDNF is linked to Parkinson disease.